GlassScriptPhysician profile
Ranjit Singh
NPI 1083159669
$4,450.07
in general payments reported to CMS, 2019-2025
21 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $294 · 2022: $862 · 2023: $1,348 · 2024: $758 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,579 · Travel and Lodging: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,578.77 |
| Travel and Lodging | $715.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $954.94 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Biotronik INC. | $715.08 | 2025 | |
| Glaxosmithkline, LLC. | $628.72 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $530.97 | 2022-2025 | Mounjaro, Jardiance, Kisunla |
| Abbvie INC. | $464.99 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.44 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $226.03 | 2021-2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $126.14 | 2021-2024 | |
| Axsome Therapeutics, INC. | $88.17 | 2023-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $67.00 | 2022-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $59.92 | 2023-2024 | Rexulti |
| Pfizer INC. | $55.39 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $48.25 | 2021-2023 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $46.32 | 2021 | |
| Novartis Pharmaceuticals Corporation | $45.38 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $27.61 | 2022 | |
| Exact Sciences Corporation | $16.97 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $16.63 | 2024 | Voquezna |
| Tris Pharma INC | $16.20 | 2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $13.13 | 2022 | |
| Abbott Laboratories | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.